Navigation Links
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Date:11/15/2011

survival with Vectibix.

Retrospective subset analyses of mCRC trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Vectibix is not recommended for the treatment of mCRC with these mutations.(7)

Important U.S. Product Safety Information (Monotherapy)

WARNING: DERMATOLOGIC TOXICITY and INFUSION REACTIONS

Dermatologic Toxicity: Dermatologic toxicities occurred in 89 percent of patients and were severe (NCI-CTC grade 3 or higher) in 12 percent of patients receiving Vectibix monotherapy. [See Dosage and Administration (2.1), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].

Infusion Reactions: Severe infusion reactions occurred in approximately one percent of patients. Fatal infusion reactions occurred in postmarketing experience [See Dosage and Administration (2.1), Warnings and Precautions (5.2), and Adverse Reactions (6.1, 6.3)].

The most common adverse events of Vectibix are skin rash with variable presentations, hypomagnesemia, paronychia, fatigue, abdominal pain, nausea, and diarrhea, including diarrhea resulting in dehydration.

Important European Product Safety Information

  • Vectibix has been approved in the European Union for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC):
    • in first-line in combination with FOLFOX
    • in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan)
    • as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
  • Vectibix is contraindicated in patients with a history of severe or life-threatening hypersensitivity reactions to the product and in patients with in
    '/>"/>

SOURCE Amgen Europe GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
5. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
6. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
7. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
8. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
10. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... Aug. 28, 2015  IP Shakti, LLC, today announced that ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... "Our new corporate identity signifies our transformation into a company ... analytics platform for patent claim validity." ... the proprietary AIA Shield™ platform, the Company commenced a corporate ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... , MARQUETTE, Mich. , Jan. 29 ... medical devices, announced today the company,s plan to open a ... 1, 2010 .  The new facility provides Pioneer greater recruiting ... growth and development of Pioneer,s Spine Division.  In addition, the ...
... PITTSBURGH , Jan. 29 Mylan Inc. ... Pharmaceuticals Inc. received final approval from the U.S. Food and ... for Polyethylene Glycol 3350 and Electrolytes for Oral Solution, USP, ... Polyethylene Glycol 3350 and Electrolytes for Oral Solution had U.S. ...
Cached Medicine Technology:Pioneer(R) Surgical Technology, Inc. Announces New Expansion Plan 2Mylan Receives Approval for Generic Version of GoLytely(R) 2
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for ... subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk ... believe that together, a difference can be made. Walkers can participate in the cause ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily on August ... for results that last for two years, the longest of any cellulite reduction system ... looking for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, ... as sponsor of the “Music With A Mission” benefit concert in Mendon, IL. Held ... was to raise money to support music education programs in the underfunded local school ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint ... grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in a ... for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, ... diagramming network and data center assets and audio-video devices, recently released Visio Stencils ... 5000 Series, HP ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... measuring how closely people follow dietary recommendations contained in tools ... been deveoped by researchers at the University of Alabama.//, According ... the children get older. ,The dual purposes of ... of a new measure of adherence to dietary recommendations and ...
... clothes treated with the common insecticide permethrin can reduce the ... study.// ,The conclusion was arrived at after Elizabeth Kimani ... and other researchers studied Somalian refugees living in camps in ... is 4.4 people, and only three percent of households have ...
... is still fresh in the memory. There are a whole ... adequate measure’ is considered extremely crucial.// It is better to ... in evolving suitable strategies against a potential Tsunami onslaught. , ... begin the exercise of delving into the seabed of Andaman ...
... was being treated for a bowel complaint, now faces the risk ... the hospital. // His left foot became infected when he was ... sent home, but returned four months later only to learn that ... the point of losing my leg. I feel really let down ...
... developed by Dr. Edward A. Hirschowitz and Dr. Li Zhong could ... at high risk for developing the disease. // Lung cancers ... around the world mainly because of the disease being diagnosed at ... is 49% higher than the national rate. However, the blood ...
... nitric oxide can significantly lower the risk of lung and ... but children must be studied for several years to assess ... , ,A clinical trial led by John Kinsella, MD, ... Children’s Hospital in Denver and a professor of pediatrics at ...
Cached Medicine News:Health News:Adherence to Dietary Recommendations Measured 2Health News:Adherence to Dietary Recommendations Measured 3Health News:New Blood Test For Early Detection Of Lung Cancer 2Health News:Early Nitric Oxide Treatment Can Help Low Birth Weight Preemies 2Health News:Early Nitric Oxide Treatment Can Help Low Birth Weight Preemies 3
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... The MonoPrep LBP Processor is a primary ... specimen collection, accessioning, processing, sampling, and slide ... data management. The MonoPrep LBP Processor produces ... from a broad range of cytology specimen ...
Medicine Products: